DE69112207T2 - "walk-through"-mutagenese. - Google Patents

"walk-through"-mutagenese.

Info

Publication number
DE69112207T2
DE69112207T2 DE69112207T DE69112207T DE69112207T2 DE 69112207 T2 DE69112207 T2 DE 69112207T2 DE 69112207 T DE69112207 T DE 69112207T DE 69112207 T DE69112207 T DE 69112207T DE 69112207 T2 DE69112207 T2 DE 69112207T2
Authority
DE
Germany
Prior art keywords
antibodies
libraries
amino acids
mutagenesis
mutants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69112207T
Other languages
English (en)
Other versions
DE69112207D1 (en
Inventor
Roberto Crea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioren LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69112207D1 publication Critical patent/DE69112207D1/de
Publication of DE69112207T2 publication Critical patent/DE69112207T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
DE69112207T 1990-04-05 1991-04-05 "walk-through"-mutagenese. Expired - Lifetime DE69112207T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50531490A 1990-04-05 1990-04-05
PCT/US1991/002362 WO1991015581A1 (en) 1990-04-05 1991-04-05 Walk-through mutagenesis

Publications (2)

Publication Number Publication Date
DE69112207D1 DE69112207D1 (en) 1995-09-21
DE69112207T2 true DE69112207T2 (de) 1996-03-28

Family

ID=24009833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69112207T Expired - Lifetime DE69112207T2 (de) 1990-04-05 1991-04-05 "walk-through"-mutagenese.

Country Status (8)

Country Link
US (3) US5798208A (de)
EP (1) EP0527809B1 (de)
JP (2) JP4251406B2 (de)
AT (1) ATE126535T1 (de)
CA (1) CA2079802C (de)
DE (1) DE69112207T2 (de)
ES (1) ES2078518T3 (de)
WO (1) WO1991015581A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194807A1 (en) * 1992-11-02 2003-10-16 Roberto Crea Walk-through mutagenesis
ATE210724T1 (de) * 1993-04-09 2001-12-15 Catalytic Antibodies Inc Selektion von genen katalytischer antikörper
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US6063562A (en) * 1994-09-16 2000-05-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst
US5602021A (en) * 1994-12-29 1997-02-11 Catalytic Antibodies, Inc. Method for generating proteolytic enzymes specific against a selected peptide sequence
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
DE69720043T2 (de) * 1996-12-20 2003-10-16 Unilever Nv Enzymatische bleichmittelzusammensetzung
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
DE19731990A1 (de) * 1997-07-25 1999-01-28 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung und Identifizierung von neuen Hydrolasen mit verbesserten Eigenschaften
US6670127B2 (en) * 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
AU2346199A (en) * 1998-01-30 1999-08-16 Sepracor, Inc. Gene regulator fusion proteins and methods of using the same for determining resistance of a protein to a drug targeted thereagainst
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
EP1073710A4 (de) * 1999-02-04 2007-12-19 Verenium Corp Nicht-stochastische erzeugung von genetischen impfstoffen und enzymen
JP3399518B2 (ja) * 1999-03-03 2003-04-21 インターナショナル・ビジネス・マシーンズ・コーポレーション 半導体構造およびその製造方法
JP2002537836A (ja) * 1999-03-09 2002-11-12 ディベルサ コーポレーション 定方向進化におけるエンドセレクション
US6251604B1 (en) 1999-08-13 2001-06-26 Genopsys, Inc. Random mutagenesis and amplification of nucleic acid
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
WO2001064864A2 (en) * 2000-02-28 2001-09-07 Maxygen, Inc. Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation
WO2001073000A2 (en) * 2000-03-24 2001-10-04 Maxygen, Inc. Methods for modulating cellular and organismal phenotypes
US8288322B2 (en) * 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
EP2308982B1 (de) * 2000-04-17 2014-11-26 Dyax Corp. Verfahren zur Einrichtung von Bibliotheken für genetische Verpackungen unterschiedlicher Familien von Peptiden
CA2411139A1 (en) * 2000-06-08 2001-12-13 James T. Willerson Inhibitors of c-reactive protein induced inflammation
FR2813314B1 (fr) * 2000-08-25 2004-05-07 Biomethodes Procede de mutagenese dirigee massive
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
PT2316940E (pt) 2000-12-18 2013-10-16 Dyax Corp Bibliotecas orientadas de pacotes genéticos
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
JP2004532038A (ja) * 2001-05-17 2004-10-21 ディヴァーサ コーポレイション 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20040096826A1 (en) * 2002-01-30 2004-05-20 Evans Glen A. Methods for creating recombination products between nucleotide sequences
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20030199068A1 (en) * 2002-03-05 2003-10-23 Bott Richard R. High throughput mutagenesis screening method
US20030171543A1 (en) * 2002-03-05 2003-09-11 Bott Richard R. High throughput mutagenesis screening method
CA2482863A1 (en) 2002-04-17 2003-10-30 Roberto Crea Universal libraries for immunoglobulins
NZ535928A (en) * 2002-04-17 2006-09-29 Roberto Crea Determining the ratio of prototype nucleotides to predetermined nucleotides, which is preferably greater than 1:1, by doping in walk-through mutagenesis
DE60312507T3 (de) * 2002-05-17 2011-08-18 Alligator Bioscience Ab Eine methode zur in vitro molekularen evolution der proteinfunktion
EP2275536A1 (de) 2002-08-06 2011-01-19 Verdia, Inc. AP1-Aminoxidase-Varianten
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
JP2007524380A (ja) 2003-04-02 2007-08-30 ボード オブ リージェンツ ザ ユニバーティー オブ テキサス システム 抗腫瘍効果をもつＢｉｋ変異型
SG155063A1 (en) 2003-04-29 2009-09-30 Pioneer Hi Bred Int Novel glyphosate-n-acetyltransferase (gat) genes
ES2609102T3 (es) * 2003-06-27 2017-04-18 Bioren, LLC Mutagénesis por revisión
EP2325339A3 (de) 2003-09-09 2011-11-02 Integrigen, Inc. Verfahren und zusammensetzungen zur Erzeugung menschlicher keimlinien-Antikörpergene
BRPI0513155B1 (pt) * 2004-07-06 2021-07-20 Bioren, Inc. Método de distinguir um ou mais resíduos de aminoácido funcionais dos resíduos de aminoácido não-funcionais em uma região definida dentro de um polipeptídeo, método de gerar uma biblioteca de análogos de polipeptídeo e método de identificar um subconjunto de análogos de polipeptídeo tendo uma propriedade desejada
BRPI0511448A (pt) * 2004-07-06 2007-12-26 Bioren Inc anticorpos anti-tnf-alfa de alta afinidade, método para a geração dos mesmos e biblioteca de seqüências
ES2563491T3 (es) 2004-07-06 2016-03-15 Bioren, LLC Bibliotecas universales de anticuerpos
WO2006114700A2 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
WO2007030668A2 (en) * 2005-09-07 2007-03-15 Jennerex Biotherapeutics Ulc Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
JP2009515516A (ja) 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CA2652452C (en) 2006-05-15 2018-07-31 Sea Lane Biotechnologies, Llc Neutralizing antibodies to influenza viruses
US20080108513A1 (en) * 2006-06-01 2008-05-08 Northwestern University Cellular Arrays
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
CA2666968A1 (en) 2006-10-20 2008-10-30 Arizona Board Of Regents For And On Behalf Of Arizona State University Modified cyanobacteria
WO2009008908A2 (en) 2007-02-12 2009-01-15 Codexis, Inc. Structure-activity relationships
US20100106585A1 (en) * 2007-04-17 2010-04-29 American Express Travel Related Services Company, Inc. System and method for evaluating positive behavior and offering incentives based upon limited use identifier transactions
EP2222846B1 (de) * 2007-08-10 2017-05-03 Protelix, Inc. Universelle fibronectin-typ iii-bindungsdomäne-bibliotheken
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
MX344415B (es) 2007-09-14 2016-12-15 Adimab Inc Bancos de anticuerpos sinteticos, designados racionalmente y usos para los mismos.
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR20100097716A (ko) 2007-11-27 2010-09-03 아블린쓰 엔.브이. 이종이량체 사이토킨 및/또는 이의 수용체에 대한 아미노산 서열과 이를 포함하는 폴리펩티드
US9873957B2 (en) * 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
CA3049612C (en) 2008-04-24 2023-01-10 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
PT2439212T (pt) 2008-05-02 2017-03-29 Novartis Ag Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações
CN102177438A (zh) 2008-07-25 2011-09-07 理查德·W·瓦格纳 蛋白筛选方法
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
US8987433B2 (en) 2009-03-27 2015-03-24 Sapphire Energy, Inc. Variant isoprenoid producing enzymes and uses thereof
US10618964B2 (en) 2009-04-10 2020-04-14 Ablynx N.V. Nanobody against IL-6R
SG174862A1 (en) 2009-04-10 2011-11-28 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
KR101852204B1 (ko) 2009-06-05 2018-04-26 아블린쓰 엔.브이. 기도 감염의 예방 및/또는 치료를 위한 일가, 이가 및 삼가 항 인간 호흡기 세포융합 바이러스 (ｈｒｓｖ) 나노바디 구조물
EP3409119B1 (de) 2009-09-14 2020-08-12 SillaJen Biotherapeutics, Inc. Krebskombinationstherapie mit onkolytischem vaccinia virus
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
ES2691717T3 (es) 2009-10-30 2018-11-28 Novartis Ag Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2507262A1 (de) 2009-11-30 2012-10-10 Ablynx N.V. Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
MX337062B (es) 2009-12-10 2016-02-11 Ottawa Hospital Res Inst Rabdovirus oncolítico.
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
CN103282560B (zh) 2010-07-16 2016-08-03 阿迪马布有限责任公司 抗体文库
EP3248987A1 (de) 2010-07-30 2017-11-29 Novartis AG Fibronectin-cradle-moleküle und bibliotheken
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity
WO2012094386A1 (en) 2011-01-04 2012-07-12 Jennerex Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
ES2627529T3 (es) 2011-06-08 2017-07-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Composiciones para tratamiento de glioblastoma
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
SI2771022T1 (sl) 2011-10-11 2020-12-31 Viela Bio, Inc. CD40L-specifična ogrodja pridobljena iz TN3 in postopki njihove uporabe
CN104144945A (zh) 2012-03-02 2014-11-12 埃博灵克斯股份有限公司 结合铜绿假单胞菌pcrv的单可变结构域抗体
CA2872096A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
AU2014236162A1 (en) 2013-03-14 2015-09-17 Arzeda Corp. Compositions having dicamba decarboxylase activity and methods of use
US20140289906A1 (en) 2013-03-14 2014-09-25 Pioneer Hi-Bred International, Inc. Compositions Having Dicamba Decarboxylase Activity and Methods of Use
EP3209327A1 (de) 2014-10-21 2017-08-30 Ablynx N.V. Behandlung von il-6r-bedingten erkrankungen
CA2977675A1 (en) 2015-03-12 2016-09-15 Medimmune, Llc Method of purifying albumin-fusion proteins
WO2016164708A1 (en) 2015-04-10 2016-10-13 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
WO2016187101A2 (en) 2015-05-21 2016-11-24 Full Spectrum Genetics, Inc. Method of improving characteristics of proteins
MA45455A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US11891634B2 (en) 2017-06-23 2024-02-06 The Board Of Trustees Of The Leland Stanford Junior University PDE5A destabilizing domains
US11891426B2 (en) 2017-12-15 2024-02-06 Aleta Biotherapeutics Inc. CD19 variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130597A (ja) * 1984-07-20 1986-02-12 Nippon Zeon Co Ltd ポリヌクレオチド合成装置
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
AU633003B2 (en) * 1988-05-11 1993-01-21 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
ATE151110T1 (de) * 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
FI87028C (fi) * 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd Metod foer att reglera effekt hos en spaenningsstyrd effektfoerstaerkare och koppling foer anvaendning i metoden
US5264563A (en) * 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons

Also Published As

Publication number Publication date
US5798208A (en) 1998-08-25
AU7741891A (en) 1991-10-30
CA2079802A1 (en) 1991-10-06
EP0527809A1 (de) 1993-02-24
JP4251406B2 (ja) 2009-04-08
JP2003135084A (ja) 2003-05-13
US5830650A (en) 1998-11-03
DE69112207D1 (en) 1995-09-21
JP4275922B2 (ja) 2009-06-10
ES2078518T3 (es) 1995-12-16
CA2079802C (en) 2001-09-18
AU653152B2 (en) 1994-09-22
EP0527809B1 (de) 1995-08-16
US6649340B1 (en) 2003-11-18
WO1991015581A1 (en) 1991-10-17
ATE126535T1 (de) 1995-09-15
JPH05506580A (ja) 1993-09-30

Similar Documents

Publication Publication Date Title
DE69112207T2 (de) "walk-through"-mutagenese.
BRPI0412007A (pt) mutagênese look-through
ES2078907T3 (es) Metodo para radiomarcar proteinas.
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
DK532284A (da) Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
DE69941701D1 (de) Mutanten von flt3-l und ihre verwendungen
DE68922338T2 (de) Entfernung von Protein A aus Antikörper-Präparationen.
FR2705341B1 (fr) Procédé de préparation de mélanges d'acides aminés N-acylés, mélanges d'acides alpha aminés N-acylés, et leurs utilisations.
DK0770876T3 (da) En screening-fremgangsmåde til at identificere ligander for målproteiner
DE68903576T2 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
KR900012626A (ko) 하이브리드 단백질, 이의 생산방법 및 이를 함유하는 약제학적 조성물
PE42695A1 (es) Procedimiento para producir proteina c
ES2109225T3 (es) Anticuerpos, su produccion y uso.
NO891713D0 (no) Monoklonale antistoffer til vevplasminogenaktivator (t-pa)
CA2004387A1 (en) Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
DE3880122D1 (de) Verfahren zur solubilisierung von unloeslichem protein.
EA199900663A1 (ru) Новые белки, связывающиеся с рецептором 1 интерферона, кодирующая их днк и способы модуляции клеточного ответа на интерфероны
DE8817263U1 (de) Enzymimmunoassay zum Nachweis von Anti-Tetanus-Antikörpern
DE3784891D1 (de) Verfahren zur isolierung von saeurestabilen, biologisch aktiven proteinen.
IT8149058A0 (it) Metodo per ottimizzare la combustione di combustibili granulari o in piccolissimi pezzi e impianto per la sua realizzazione

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOREN, INC. (N.D.GES.D. STAATES DELAWARE), SA, US

8381 Inventor (new situation)

Inventor name: CREA, ROBERTO, CHESTNUT HILL, MASS., US